Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

pertuzumab

- PMLiVE

FDA clears Roche’s breakthrough drug Gazyva

First drug approved in US under new scheme

Roche - Basel

Roche signs €400m superbug deal

Buys rights to investigational antibiotic from Polyphor

- PMLiVE

To name and shame substandard healthcare?

Improving care by ‘naming and shaming’ hospitals or doctors remains a thorny issue

- PMLiVE

Driving good practice in homecare

The release of new professional standards looks to underpin the quality, and continued rise, of homecare services in the UK

- PMLiVE

Buildings light up pink for breast cancer

Part of 'Wear it pink' day for  Breast Cancer Campaign

- PMLiVE

Novartis’ Lucentis wins fourth NICE recommendation

But eye drug only recommended after a price-cutting patient access scheme offered

- PMLiVE

Former Blair adviser to lead NHS England

Simon Stevens to succeed David Nicholson

- PMLiVE

Celgene’s Revlimid knocked-back by NICE

Final draft guidance from NICE does not recommend drug for rare bone marrow disorder

- PMLiVE

Roche signs biologics partnership with Samsung

Manufacturing deal follows investment in pharma firm's own capabilities

- PMLiVE

Amgen buys total filgrastim rights from Roche

Wrests control of white blood cell stimulator franchise

Novartis building

NICE backs Novartis/ ThromboGenics’ eye drug

Recommends Jetrea for NHS use in England and Wales to treat the rare disease vitreomacular traction

- PMLiVE

Walgreens: UK homecare sector could learn from the US

Pharmacy chain calls on UK to focus more on measuring the benefits of homecare

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links